Genocea Biosciences (Genocea Biosciences) Total Inventories : $0.00 Mil (As of Mar. 2022)

View and export this data going back to 2014. Start your Free Trial

What is Genocea Biosciences Total Inventories?

Genocea Biosciences's total inventories for the quarter that ended in Mar. 2022 was $0.00 Mil. Genocea Biosciences's average total inventories from the quarter that ended in Dec. 2021 to the quarter that ended in Mar. 2022 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Genocea Biosciences's Net-Net Working Capital per share for the quarter that ended in Mar. 2022 was $-0.11.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Genocea Biosciences's Inventory-to-Revenue for the quarter that ended in Mar. 2022 was 0.00.

Genocea Biosciences Total Inventories Historical Data

The historical data trend for Genocea Biosciences's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genocea Biosciences Total Inventories Chart

Genocea Biosciences Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Total Inventories

Get a 7-Day Free Trial

Genocea Biosciences Quarterly Data
	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Genocea Biosciences Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Genocea Biosciences (OTCPK:GNCAQ) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Genocea Biosciences's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2022 is

	Net-Net Working Capital Per Share (Q: Mar. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(20.137	+	0.75 * 0	+	0.5 * 0	-	26.403
-	0	-	0)	/	58.7338
=	-0.11

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Genocea Biosciences's Days Inventory for the three months ended in Mar. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Mar. 2022 )	/	Cost of Goods Sold (Q: Mar. 2022 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Genocea Biosciences's Inventory Turnover for the quarter that ended in Mar. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Mar. 2022 )	/	Average Total Inventories (Q: Mar. 2022 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Genocea Biosciences's Inventory to Revenue for the quarter that ended in Mar. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Mar. 2022 )	/	Revenue (Q: Mar. 2022 )
	=	0	/	0.27
	=	0.00

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Genocea Biosciences Total Inventories Related Terms

Thank you for viewing the detailed overview of Genocea Biosciences's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Genocea Biosciences (Genocea Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genocea Biosciences Inc (OTCPK:GNCAQ) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Acorn Park Drive, Cambridge, MA, USA, 02140

Website

https://www.genocea.com

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns a pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines.

Executives

Jacquelyn L Sumer	officer: CHIEF LEGAL & COMPLIANCE OFF	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
William D Clark	director, officer: President and CEO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
George Siber	director	2000 BROADWAY, PENTHOUSE 2B, NEW YORK NY 10023
Diantha Duvall	officer: CHIEF FINANCIAL OFFICER	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Scott D Sandell	10 percent owner
Stapleton Raymond D Jr	officer: EVP PHARM SCI & MFG	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jessica Baker Flechtner	officer: VP of Research	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Carmen Chang	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
New Enterprise Associates 16, L.p.	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Paul Edward Walker	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Ali Behbahani	director	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Forest Baskett	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815